http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 15 Jul 2026 07:39:47 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Cardiol+Therapeutics+%28CRDL%29/26770936.html <p>H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $9.00 price target on Cardiol Therapeutics (NASDAQ: CRDL).</p><p>The analyst commented: "We view the publication of the MAvERIC-Pilot study in the Journal of the American Heart Association as a positive for CRDL and further validates our confidence ahead of the Phase III MAVERIC trial readout in 1Q27. The paper confirms rapid and durable improvements in pericarditis pain, provides greater confidence in the objective CRP response, and shows that most patients remained recurrence-free while background therapies were withdrawn. The publication also validates the potential commercial positioning of CardiolRx as an oral, steroid-sparing http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Cardiol+Therapeutics+%28CRDL%29/26770936.html Wed, 15 Jul 2026 07:39:47 -0400 CRDL http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+Jul+14/26764873.html si-local-file:///var/storage/secattach/20260714/26764873.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+Jul+14/26764873.html Tue, 14 Jul 2026 07:38:00 -0400 CRDL O.40774130 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+Jul+14/26764873.html si-local-file:///var/storage/secattach/20260714/26764873.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+Jul+14/26764873.html Tue, 14 Jul 2026 07:38:00 -0400 CRDL O.40774130 http://www.streetinsider.com/Corporate+News/Cardiol+Therapeutics+Phase+II+pericarditis+study+published+in+JAHA/26764790.html <p>Cardiol Therapeutics Inc. (NASDAQ: CRDL) announced that results from its Phase II MAvERIC-Pilot study have been published in the <em>Journal of the American Heart Association</em>, according to a company statement dated July 14, 2026.</p><p>The publication covers findings in which the company's drug candidate, CardiolRx™, was associated with reductions in pericarditis pain and inflammation in patients with high baseline disease burden. The study also reported reductions in pericarditis episodes per year and a favorable safety and tolerability profile.</p><p>The Phase II findings had previously been presented at the American Heart Association Scientific Sessions. Their peer-reviewed publication makes the full data available to http://www.streetinsider.com/Corporate+News/Cardiol+Therapeutics+Phase+II+pericarditis+study+published+in+JAHA/26764790.html Tue, 14 Jul 2026 07:28:24 -0400 CRDL http://www.streetinsider.com/FDA/Cardiol+Therapeutics+Phase+II+pericarditis+study+published+in+JAHA/26764790.html <p>Cardiol Therapeutics Inc. (NASDAQ: CRDL) announced that results from its Phase II MAvERIC-Pilot study have been published in the <em>Journal of the American Heart Association</em>, according to a company statement dated July 14, 2026.</p><p>The publication covers findings in which the company's drug candidate, CardiolRx™, was associated with reductions in pericarditis pain and inflammation in patients with high baseline disease burden. The study also reported reductions in pericarditis episodes per year and a favorable safety and tolerability profile.</p><p>The Phase II findings had previously been presented at the American Heart Association Scientific Sessions. Their peer-reviewed publication makes the full data available to http://www.streetinsider.com/FDA/Cardiol+Therapeutics+Phase+II+pericarditis+study+published+in+JAHA/26764790.html Tue, 14 Jul 2026 07:28:24 -0400 CRDL http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html <div class="xn-content"> <p class="prntac"><i>• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.</i></p><p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRDL" idsrc="xmltag.org" >Cardiol Therapeutics Inc.</span> (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of its Phase II MAvERIC study results in the <i><span>Journal of the American Heart Association</span></i> ("<i>JAHA</i>"). The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html Tue, 14 Jul 2026 07:27:00 -0400 A.19238921 CRDL CRDL O.16809625 O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html <div class="xn-content"> <p class="prntac"><i>• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.</i></p><p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRDL" idsrc="xmltag.org" >Cardiol Therapeutics Inc.</span> (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of its Phase II MAvERIC study results in the <i><span>Journal of the American Heart Association</span></i> ("<i>JAHA</i>"). The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html Tue, 14 Jul 2026 07:27:00 -0400 A.19238921 CRDL CRDL O.16809625 O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html <div class="xn-content"> <p class="prntac"><i>• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.</i></p><p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRDL" idsrc="xmltag.org" >Cardiol Therapeutics Inc.</span> (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of its Phase II MAvERIC study results in the <i><span>Journal of the American Heart Association</span></i> ("<i>JAHA</i>"). The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html Tue, 14 Jul 2026 07:27:00 -0400 A.19238921 CRDL CRDL O.16809625 O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html <div class="xn-content"> <p class="prntac"><i>• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.</i></p><p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRDL" idsrc="xmltag.org" >Cardiol Therapeutics Inc.</span> (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of its Phase II MAvERIC study results in the <i><span>Journal of the American Heart Association</span></i> ("<i>JAHA</i>"). The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html Tue, 14 Jul 2026 07:27:00 -0400 A.19238921 CRDL CRDL O.16809625 O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html <div class="xn-content"> <p class="prntac"><i>• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.</i></p><p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRDL" idsrc="xmltag.org" >Cardiol Therapeutics Inc.</span> (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of its Phase II MAvERIC study results in the <i><span>Journal of the American Heart Association</span></i> ("<i>JAHA</i>"). The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html Tue, 14 Jul 2026 07:27:00 -0400 A.19238921 CRDL CRDL O.16809625 O.40774130 http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html <div class="xn-content"> <p class="prntac"><i>• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.</i></p><p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRDL" idsrc="xmltag.org" >Cardiol Therapeutics Inc.</span> (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of its Phase II MAvERIC study results in the <i><span>Journal of the American Heart Association</span></i> ("<i>JAHA</i>"). The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html Tue, 14 Jul 2026 07:27:00 -0400 A.19238921 CRDL CRDL O.16809625 O.40774130 http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html <div class="xn-content"> <p class="prntac"><i>• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.</i></p><p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRDL" idsrc="xmltag.org" >Cardiol Therapeutics Inc.</span> (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of its Phase II MAvERIC study results in the <i><span>Journal of the American Heart Association</span></i> ("<i>JAHA</i>"). The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html Tue, 14 Jul 2026 07:27:00 -0400 A.19238921 CRDL CRDL O.16809625 O.40774130 http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html <div class="xn-content"> <p class="prntac"><i>• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.</i></p><p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRDL" idsrc="xmltag.org" >Cardiol Therapeutics Inc.</span> (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of its Phase II MAvERIC study results in the <i><span>Journal of the American Heart Association</span></i> ("<i>JAHA</i>"). The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html Tue, 14 Jul 2026 07:27:00 -0400 A.19238921 CRDL CRDL O.16809625 O.40774130 http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html <div class="xn-content"> <p class="prntac"><i>• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.</i></p><p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRDL" idsrc="xmltag.org" >Cardiol Therapeutics Inc.</span> (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of its Phase II MAvERIC study results in the <i><span>Journal of the American Heart Association</span></i> ("<i>JAHA</i>"). The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html Tue, 14 Jul 2026 07:27:00 -0400 A.19238921 CRDL CRDL O.16809625 O.40774130 http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html <div class="xn-content"> <p class="prntac"><i>• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.</i></p><p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CRDL" idsrc="xmltag.org" >Cardiol Therapeutics Inc.</span> (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of its Phase II MAvERIC study results in the <i><span>Journal of the American Heart Association</span></i> ("<i>JAHA</i>"). The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics%27+Phase+II+Recurrent+Pericarditis+Data+Published+in+the+Journal+of+the+American+Heart+Association/26764787.html Tue, 14 Jul 2026 07:27:00 -0400 A.19238921 CRDL CRDL O.16809625 O.40774130 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+Jul+09/26750265.html si-local-file:///var/storage/secattach/20260709/26750265.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+Jul+09/26750265.html Thu, 09 Jul 2026 07:53:00 -0400 CRDL O.40774130 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+Jul+09/26750265.html si-local-file:///var/storage/secattach/20260709/26750265.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+Jul+09/26750265.html Thu, 09 Jul 2026 07:53:00 -0400 CRDL O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26750076.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ - <span value="NASDAQ-NMS:CRDL" idsrc="xmltag.org" >Cardiol Therapeutics Inc.</span> (NASDAQ: CRDL) (TSX: CRDL) ("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle &amp; Vision Summit in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, MA</location>, on <chron>July 16, 2026</chron>, at <chron>12:20 p.m. EDT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26750076.html Thu, 09 Jul 2026 07:27:00 -0400 CRDL CRDL O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26750076.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ - <span value="NASDAQ-NMS:CRDL" idsrc="xmltag.org" >Cardiol Therapeutics Inc.</span> (NASDAQ: CRDL) (TSX: CRDL) ("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle &amp; Vision Summit in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, MA</location>, on <chron>July 16, 2026</chron>, at <chron>12:20 p.m. EDT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26750076.html Thu, 09 Jul 2026 07:27:00 -0400 CRDL CRDL O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26750076.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ - <span value="NASDAQ-NMS:CRDL" idsrc="xmltag.org" >Cardiol Therapeutics Inc.</span> (NASDAQ: CRDL) (TSX: CRDL) ("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle &amp; Vision Summit in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, MA</location>, on <chron>July 16, 2026</chron>, at <chron>12:20 p.m. EDT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26750076.html Thu, 09 Jul 2026 07:27:00 -0400 CRDL CRDL O.40774130 http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26750076.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ - <span value="NASDAQ-NMS:CRDL" idsrc="xmltag.org" >Cardiol Therapeutics Inc.</span> (NASDAQ: CRDL) (TSX: CRDL) ("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle &amp; Vision Summit in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, MA</location>, on <chron>July 16, 2026</chron>, at <chron>12:20 p.m. EDT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26750076.html Thu, 09 Jul 2026 07:27:00 -0400 CRDL CRDL O.40774130 http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26750076.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ - <span value="NASDAQ-NMS:CRDL" idsrc="xmltag.org" >Cardiol Therapeutics Inc.</span> (NASDAQ: CRDL) (TSX: CRDL) ("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle &amp; Vision Summit in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, MA</location>, on <chron>July 16, 2026</chron>, at <chron>12:20 p.m. EDT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26750076.html Thu, 09 Jul 2026 07:27:00 -0400 CRDL CRDL O.40774130 http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26750076.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ - <span value="NASDAQ-NMS:CRDL" idsrc="xmltag.org" >Cardiol Therapeutics Inc.</span> (NASDAQ: CRDL) (TSX: CRDL) ("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle &amp; Vision Summit in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, MA</location>, on <chron>July 16, 2026</chron>, at <chron>12:20 p.m. EDT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26750076.html Thu, 09 Jul 2026 07:27:00 -0400 CRDL CRDL O.40774130 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+Jun+25/26688324.html si-local-file:///var/storage/secattach/20260625/26688324.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+Jun+25/26688324.html Thu, 25 Jun 2026 07:45:00 -0400 CRDL O.40774130 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+Jun+25/26688324.html si-local-file:///var/storage/secattach/20260625/26688324.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+Jun+25/26688324.html Thu, 25 Jun 2026 07:45:00 -0400 CRDL O.40774130